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The development and validation of a cerebral ultrasound
scoring system for infants with hypoxic-ischaemic
encephalopathy
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Irwin Reiss6, Paul Govaert6, Manon J.N.L. Benders1,2 and Jeroen Dudink1,2
BACKGROUND: Hypoxic-ischaemic encephalopathy (HIE) is an important cause of morbidity and mortality in neonates. When the
gold standard MRI is not feasible, cerebral ultrasound (CUS) might offer an alternative. In this study, the association between a novel
CUS scoring system and neurodevelopmental outcome in neonates with HIE was assessed.
METHODS: (Near-)term infants with HIE and therapeutic hypothermia, a CUS on day 1 and day 3–7 after birth and available
outcome data were retrospectively included in cohort I. CUS findings on day 1 and day 3–7 were related to adverse outcome in
univariate and the CUS of day 3–7 also in multivariable logistic regression analyses. The resistance index, the sum of deep grey
matter and of white matter involvement were included in multivariable logistic regression analyses. A comparable cohort from
another hospital was used for validation (cohort II).
RESULTS: Eighty-three infants were included in cohort I and 35 in cohort II. The final CUS scoring system contained the sum
of white matter (OR= 2.6, 95% CI 1.5–4.7) and deep grey matter involvement (OR= 2.7, 95% CI 1.7–4.4). The CUS scoring system
performed well in cohort I (AUC= 0.90) and II (AUC= 0.89).
CONCLUSION: This validated CUS scoring system is associated with neurodevelopmental outcome in neonates with HIE.
Pediatric Research (2020) 87:59–66; https://doi.org/10.1038/s41390-020-0782-0
INTRODUCTION
Hypoxic-ischaemic encephalopathy (HIE) following presumed
perinatal asphyxia is an important cause of morbidity and mortality
in neonates and can result in long-term neurological sequelae.1,2
Perinatal asphyxia can be caused by acute or subacute perinatal
hypoxia-ischaemia that both correspond with different patterns of
brain injury.3,4 Acute perinatal asphyxia often results in injury of the
deep grey nuclei, such as the basal ganglia and thalamus, or even
in near-total brain injury.5 Injury to deep grey nuclei can lead to
dyskinetic cerebral palsy, impaired cognitive outcome and
epilepsy.5 Subacute (“chronic”) perinatal asphyxia is most often
associated with watershed injury with involvement of the cortex
and subcortical white matter.5 This usually does not result in motor
impairment, but cognitive impairment and language problems
occur more frequently and disabilities become apparent in
childhood.6–8 In daily practice, the neurological prognosis is
predicted based on the triad of neuroimaging, (amplitude-
integrated) electro-encephalography ((a)EEG) and clinical features.9
Currently, the gold standard in neuroimaging is magnetic
resonance imaging (MRI).5,10,11 MRI predicts neurological outcome
in HIE based on conventional imaging i.e. with an MR scoring
system12,13 and quantitatively with apparent diffusion coefficients,
arterial spin labelling or magnetic resonance spectroscopy.14–16
MRI is the gold standard, but an alternative neuroimaging
technique is necessary because there are circumstances when the
infant is not stable enough to be transported to the MRI unit or
MRI is not available, for example in developing countries.17,18 In
these situations, cerebral ultrasound (CUS) might offer a bedside
and cheaper alternative.18 Currently, CUS is not routinely used to
predict outcome in HIE; CUS is not as sensitive as MRI in
diagnosing brain injury and may take several days to become
apparent.11,19 However, based on the available literature, CUS
might not only be complementary to MRI but in some cases the
only available neuroimaging method in HIE.19–21
A validated composite CUS scoring system is needed to assess
brain injury and to predict outcome with CUS in HIE. To the best of
our knowledge, such an ultrasound scoring system is not yet
available. The CUS scoring systems that have previously been
developed have not been validated.17,22–28 The aim of this study is
to assess the association between a novel CUS scoring system and
neurodevelopmental outcome in neonates with HIE at the age of
2 years.
METHODS
Study population
We included (near-) term infants (36.0 until 42.0 weeks of
gestational age) with HIE who were treated with hypothermia in
the University Medical Centre Utrecht between January 2008 and
July 2014, who had at least one CUS on day 1 and a second CUS
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between days 3 and 7 after birth. An additional inclusion criterion
was the availability of outcome data, either death or a
neurodevelopmental follow-up examination at the age of 2 years.
We excluded infants with metabolic or genetic abnormalities. We
used this cohort to create the scoring system (cohort I).
A different cohort with similar clinical characteristics, born in the
Erasmus Medical Centre in Rotterdam, with at least one CUS
between days 3 and 7 and available outcome data were used to
validate the scoring system (cohort II). The same inclusion and
exclusion criteria applied to this cohort. In both cohorts the CUS
scans were part of standard clinical care. The scans were
conducted by trained neonatologists, fellows in neonatology
and physician assistants with different levels of experience in CUS.
In cohort I CUS were performed using an ultrasound machine from
Toshiba (Medical System Corporation, Tokyo, Japan) and in
cohort II from Esaote (Genova, Italy). Convex 5–10 MHz and linear
15–18 MHz probes were used in both cohorts.
Development of the CUS scoring system
We searched the literature for possible CUS items to include in the
scoring system. The relevance of all these items was discussed by
a group of experts including neonatologists and a paediatric
neuroradiologist, all with many years of experience in CUS (J.D., L.
S.d.V., F.G., P.G., M.L.). Items were categorised into normal-mild,
moderate and severe or into absent and present. The same group
of experts reached consensus on the definitions of the different
categories. For examples of the items see Fig. 1 and for definitions
see Table 1. Additional antenatally acquired pathology was also
scored, i.e. porencephaly and atrophy.
After the development of the scoring system, a neonatologist,
with more than 10 years of experience in neonatal neurology
and CUS, scored all CUS in cohort I (observer 1). First, the
association between all separate items and adverse outcome
was determined. Because of multicollinearity all white matter
items were summed into a white matter score, the deep grey
matter items into a grey matter score and the resistance index
remained a separate item. Next, the association between the
different composite scores in the scoring system and adverse
outcome was calculated.
Furthermore, the additional value of day 1 CUS to diagnose
antenatally acquired pathology of the brain was determined.
Neurodevelopmental outcome
We retrospectively collected clinical parameters of all infants.
Neurodevelopmental follow-up was performed with the Bayley
Scales of Infant and Toddler Development, third edition (BSITD-III) at
the age of 2 years29 by a neonatologist and an educational therapist
or child psychologist. Adverse outcome was defined as death,
a b c d
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Fig. 1 Cerebral ultrasound, outcome and HIE: example images. a Moderate cerebral oedema (1 point), b severe cerebral oedema (2 points),
c moderate periventricular white matter (1 point), d severe periventricular white matter (2 points), e moderate subcortical white matter
(1 point), f severe subcortical white matter (2 points), g moderate thalamus (1 point), h severe thalamus (2 points), i moderate putamen
(1 point), j severe putamen (2 points), k “four-column sign” which means that both left and right thalamus and putamen are visible at the
coronal view as four columns (1 point), l visibility of the PLIC (1 point). For the scoring sheet and definitions, see Table 1.
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cerebral palsy or a cognitive/motor composite score <85 according
to the BSITD-III (United States of America norms) at 2 years of age.
Validation: inter-observer variability
A neonatologist (J.D.) and a paediatric neuroradiologist (M.L.),
both with an expertise in CUS, scored the day 1 and day 3−7 CUS
of cohort I independently of each other (observer 1 and observer
3). Observers 1 and 3 did not work in the UMC Utrecht in the
period that the CUS were conducted, so they were completely
blinded to outcome. Another neonatologist (D.V.) without a
special focus on CUS scored the CUS of 20 randomly selected
patients to determine the inter-observer agreement in daily
clinical practice (observer 2).
Validation of the scoring system in cohort II
The CUS of cohort II were scored by two neonatologists with more
than 25 years of experience in reading cerebral ultrasound scans
(F.G. and L.S.d.V.). They scored the CUS together and reached
consensus about the CUS score of all infants. The observers did
not work in the Erasmus Medical Centre at the moment the CUS
were performed, so they were completely blinded to outcome.
Validation: correlation with MRI and histology
Secondary outcomes were the correlation with MRI and histolo-
gical findings. A correlation between the CUS scoring system and
MRI was assessed using the MRI scoring system of Weeke et al.13
in cohort I. In cohort II the diffusion weighted sequences were
often of suboptimal quality; therefore, the secondary outcomes
were only analysed for cohort I.
Statistical analyses
SPSS Version 21 was used for statistical analysis (IBM Corp., Armonk
NY, USA). Differences in baseline characteristics between the two
cohorts were calculated using the independent t test or
Mann−Whitney U test for continuous variables and the χ2 test for
categorical variables. Univariate logistic regression was performed
with the CUS items as independent variables and outcome as
dependent variable. Non-significant items were excluded from
further analysis. The sum of white matter involvement, of deep grey
matter involvement and a Doppler ultrasound resistance index (RI)
of a cerebral artery ≤0.55 were calculated and included in backward
multivariable logistic regression analysis. Variables with a p value <
0.05 were entered in the model and those with a p value ≥ 0.1
deleted. The inter-observer variability and the correlation with MRI
were calculated using Spearman rank correlation test. Predictive
values and ROC curves were determined for cohorts I and II per cut-
off value. A p value < 0.05 was considered statistically significant.
RESULTS
Study population
Between January 2008 and July 2014, 145 infants with HIE were
treated with hypothermia in the University Medical Centre
Utrecht. In total, 83 infants were included in cohort I. Infants
were excluded because of genetic or congenital abnormalities
(n= 9), preterm birth < 36 weeks (n= 12), because one or both of
the CUS were not present (n= 27), only a few images of an
examination were saved (n= 2), the quality was insufficient
because of suboptimal settings (n= 6) or because of missing
outcome data (n= 6).
In the Erasmus Medical Centre, 69 infants with HIE were treated
with hypothermia in this period and 35 newborns were included
in cohort II. Infants were excluded because of genetic or
congenital abnormalities (n= 9), preterm birth < 36 weeks (n= 2),
diagnosis of arterial ischaemic stroke (n= 2), because the CUS
between days 3 and 7 was not present (n= 15) or because no
follow-up data were available (n= 6).
The incidence of death due to redirection of care between
infants who were included and infants who were excluded from
the study did not differ significantly.
Table 1. The scoring system.
Item Normal-mildly
abnormal (0)
Moderately abnormal (1) Severely abnormal (2) Total points
Impaired white/grey
matter differentiation
and/or slit-like
ventricles
Normal differentiation
between grey and white
matter and open
ventricles.
Reduced differentiation between
grey and white matter and/or slit-like
ventricles.
No differentiation between grey and white
matter and slit-like ventricles.
Hyperechogenicity
periventricular
white matter
Normal echogenicity or
minor hyperechogenicity.
Moderate or focal hyperechogenicity,
not as white as choroid plexus.
Severe and diffuse hyperechogenicity, as
white as choroid plexus.
Hyperechogenicity
subcortical
white matter
Normal echogenicity or
minor hyperechogenicity.
Focal hyperechogenicity of the
subcortical white matter. Moderate
differentiation of white and
(subcortical) grey matter.
Clear “tramlines” sign; hyperechogenicity of
subcortical white matter almost similar to
sulci with hyposignal intensity of cortex in
between.
Hyperechogenicity
thalamus
Normal echogenicity or
minor hyperechogenicity.
Moderate or focal hyperechogenicity
thalamus.
The hyperechogenicity is severe and
diffuse.
Hyperechogenicity
putamen
Normal echogenicity or
minor hyperechogenicity.
Moderate or focal hyperechogenicity
putamen
The hyperechogenicity is severe and
diffuse.
Absent (0) Present (1) Total points
Four column sign Normal echogenicity to
minor hyperechogenicity
On the coronal cUS plane there is a four column sign caused by moderate or severe
bilateral hyperechogenicity of the thalamus and putamen.
Visibility PLIC The PLIC is not visible as a
hypo-echogenic line
between the putamen
and thalamus
The PLIC is clearly visible as a hypo-echogenic line between the hyperechogenic
putamen and thalamus
White matter involvement is the sum of oedema, periventricular and subcortical white matter damage (0–6 points). Grey matter involvement includes
hyperechogenicity of the thalami, putamen, visibility of the PLIC, and four-column sign (0–6 points).
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Baseline characteristics were comparable between the two
cohorts except for Apgar scores (Table 2). The mean Apgar scores
were lower in Cohort II. Four infants had a postnatal collapse
within 2 h after birth, which explains their high Apgar scores. The
reason for incomplete hypothermia in all infants was early
rewarming because of redirection of care. The reason of death
in both cohorts was redirection of care based on a poor
neurological prognosis.
Development of the CUS scoring system
The following potential CUS items were found in the literature: slit-
like ventricles, impaired differentiation white/grey matter, “four-
column” sign, hyperechogenicity of the thalamus, putamen,
subcortical white matter, periventricular white matter, hippocam-
pus, brainstem and vermis, visibility of the posterior limb internal
capsule (PLIC) and RI of a cerebral artery ≤0.55.17,22–28,30 We
excluded hyperechogenicity of the hippocampus, vermis and
brainstem because these structures were rarely depicted on the
available CUS images. The RI was scored based on all available
ultrasounds; if the RI was ≤0.55 at one of these CUS, this item was
scored as abnormal.
The CUS scoring system and neurodevelopmental outcome on
day 1
Antenatally acquired pathology was found in 14 infants (17%).
Germinal layer cysts (n= 7), lenticulostriate vasculopathy (n= 4),
frontal horn cysts (n= 2) and porencephaly (n= 1) were
identified.
On day 1, only severe hyperechogenicity of the periventricular
white matter on CUS was significantly associated with adverse
outcome (OR= 5.0; 95% CI 1.4–18.4) in univariate logistic regres-
sion. The other items were not significantly associated with
adverse outcome. Although it did not reach significance, all infants
with hyperechogenicity of the thalamus (moderate n= 5; severe
n= 1), of the putamen (moderate n= 2) or a four-column sign
(n= 1) on day 1 had an adverse outcome.
The CUS scoring system and neurodevelopmental outcome
between days 3 and 7
Between days 3 and 7 after birth, most of the CUS items
significantly predicted adverse outcome in the univariate logistic
regression analysis (Table 3).
In the multivariable analysis the RI (0−1 point), the sum of the
deep grey matter (0–6 points) and of the white matter involvement
(0–6 points) were included. The deep grey matter involvement was
the sum of thalamus, putamen, PLIC and four-column sign
subscores. White matter involvement included oedema, subcortical
white matter and periventricular white matter subscores.
The grey and white matter subscores of cohort I on both days
are shown in Fig. 2 per outcome group.
The cumulative score of the white matter (OR= 2.6, 95% CI
1.5–4.7) and of the deep grey matter involvement (OR= 2.7, 95%
CI 1.7–4.4) between days 3 and 7 after birth were included in
the final scoring system. The RI was not significant in multivariable
logistic regression. The probability of an adverse outcome at the
age of 2 years could be calculated using the following formula: 1/
(1+ e−(−3.385+ 0.960 × white matter+ 0.995 × deep grey matter)). The CUS
scoring system performed well in cohort I (AUC= 0.90; 95% CI
0.83–0.98). Table 4 shows the performance per cut-off value.
Validation: inter-observer variability
Table 5 shows the agreement between the observers in cohort I.
There is a moderate inter-observer agreement between all three
observers.
Validation of the scoring system in cohort II
The predictive values of the scoring system in cohort II are shown
in Table 4. The AUC was 0.89 (95% CI 0.77–1.00).
To exclude the effect of the hospital on outcome, logistic
regression was performed with the total CUS score, the hospital
and their interaction term included in the analysis. The CUS score
was significantly associated with adverse outcome (OR= 2.5; 95%
CI 1.8–3.4), the hospital and their interaction term were not.
Table 2. Baseline characteristics.
Patient characteristic Cohort I (n= 83) Cohort II (n= 35) p value
Male, n (%) 50 (60.2) 19 (54.3) 0.55
Gestational age, median weeks+days (range) 40+1 (36+0–42+4) 39+6 (36+3–41+6) 0.18
Birth weight, median in gram (range) 3500 (2260–5000) 3425 (1780–4440) 0.36
Mode of delivery 0.07
Emergency caesarian section, n (%) 46 (55.4) 20 (57.1)
Vaginal delivery, n (%) 25 (30.1) 6 (17.1)
Vacuum extraction, n (%) 12 (14.5) 9 (25.7)
Apgar score at 5 min, median (range) 3 (0–10) 3 (0–9) <0.001
First pH, median (range) 6.96 (6.53–7.34) 6.94 (6.60–7.28) 0.67
Thompson score, median (range) 10 (4–19) 11 (5–20) 0.83
Sarnat classification 0.87
Mild, n (%) 5 (6.0) 5 (14.3)
Moderate, n (%) 58 (69.9) 19 (54.3)
Severe, n (%) 20 (24.1) 10 (28.6)
Incomplete hypothermia <72 h, n (%) 6 (7.2) 0 (0) 0.10
Postmenstrual age at CUS day 3–7, median days (range) 4 (3–7) 4 (3–7) 0.49
MRI available, n (%) 77 (92.8) N/A N/A
Postmenstrual age at MRI, median days (range) 6 (3–16) N/A N/A
Outcome 0.26
Normal, n (%) 54 (65.1) 17 (48.6)
Adverse outcome <85, on BSITD-III, n (%) 3 (3.6) 7 (20.0)
Death, n (%) 26 (31.3) 11 (31.4)
The development and validation of a cerebral ultrasound scoring system. . .
KV Annink et al.
62
Pediatric Research (2020) 87:59 – 66
Validation: correlation with MRI and histology
There was a moderate correlation between the CUS and MRI
scoring system in cohort I (Spearman’s rho= 0.67; p < 0.001;
Fig. 3). In the six most severely affected infants, an MRI was not
feasible because the infants were clinically too unstable.
Of the 26 infants in cohort I that died during the neonatal
period, 17 infants (65%) underwent postmortem examination. In
all these 17 infants, CUS abnormalities were confirmed with
histology. The histological damage was more extensive than
diagnosed with CUS.
DISCUSSION
We developed a scoring system to structurally score CUS
abnormalities in (near)-term infants with HIE. The scoring system
was associated with neurodevelopmental outcome and includes
composite scores of white matter and deep grey matter
involvement, both of which contain multiple separate items. This
scoring system was developed based on the CUS between days 3
and 7 after birth; the CUS on day 1 after birth was not predictive of
adverse outcome. The CUS scoring system was validated in
another cohort and the performance was relatively good.
To the best of our knowledge, this is the first CUS scoring system
using a validated composite score to predict an adverse outcome.
Currently, three CUS scoring systems for infants with HIE are
available. A CUS scoring system for asphyxiated infants in Uganda
has recently been reported.17 This scoring system was used to
identify early HIE-related brain damage but did not provide
predictive values.17 Two other scoring systems were developed to
score patterns of brain injury in HIE. Leijser et al.26 scored
combinations of white and grey matter involvement and
compared CUS and MRI. The other CUS scoring system by Swarte
et al.28 defined six different patterns, for example, the combination
of deep grey matter involvement and extensive cortical involve-
ment. These scoring systems did not allow different items to be
scored within the categories separately. For example, when
describing deep grey matter involvement, this may imply that
the left and right thalamus are affected but the basal ganglia are
not, while it is of importance to distinguish between just thalamic
involvement and thalamic and basal ganglia involvement.
Furthermore, they combined white and grey matter involvement,
even though different types of brain injury might lead to different
outcomes.5 For these reasons, we developed a CUS scoring system
based on composite scores, which might be easier to use in clinical
practice. The composite scores for deep grey matter and white
matter involvement had to be summed because of multicollinear-
ity. However, it remains possible to score the different items
separately and to make a distinction between white matter and
deep grey matter involvement. Additionally, this is the first CUS
scoring system in HIE that is validated in another cohort.
As expected, all scored items on day 3−7 in the univariate
analysis were significant predictors of adverse outcome. These
items have all been described as asphyxia-related brain
injury.19,23,25,26,30–32 Asphyxia-related brain injury is more common
in HIE, but as many as 34.2% of controls also showed
periventricular hyperechogenicity and 9.2% slit-like ventricles
shortly after birth.22 Further, Eken et al. correlated hyperecho-
genicity on CUS with histological findings: hyperechogenicity of
the thalamus occurred within 72 h after birth on CUS (sensitivity
100%, specificity 83.3% of CUS compared to histology), hyper-
echogenicity of the periventricular white matter within 24 h
Table 3. Univariate association of the items on CUS (day 3–7) and
adverse outcome.
Item Category Patients per
category, n
OR (95% CI)
Cerebral oedema Normal-mild 70 –
Moderate 12 14.4 (2.9–72.3)
Severe 1
Thalamus Normal-mild 45 –
Moderate 32 26.7 (6.7–106.2)
Severe 5
Putamen Normal-mild 66 –
Moderate 15 7.9 (2.2–28.2)
Severe 1
Four-column sign Normal 67 –
Abnormal 14 10.0 (2.5–39.9)
PLIC Normal 59 –
Abnormal 23 11.1 (3.6–34.2)
Periventricular
white matter
Normal-mild 32 –
Moderate 43 9.2 (2.4–34.9)
Severe 8 16.1 (2.5–103.6)
Subcortical
white matter
Normal-mild 42 –
Moderate 35 4.0 (1.5–11.1)
Severe 6 8.5 (1.3–54.8)
Resistance index Normal 60 –
Abnormal 8 16.3 (1.9–142.6)
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Fig. 2 Cerebral ultrasound, outcome and HIE: subscores. Grey
matter subscores (a) and white matter subscores (b) of cohort I on
day 1 and day 3−7, categorised for outcome.
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(sensitivity 100%, specificity 83.3%) and hyperechogenicity of the
cortex within 72 h (sensitivity 76.9%, specificity 100%). Additional
lesions, not identified by CUS, were found in the brainstem,
hippocampus and cerebellum with histology.21 These three items
were not included in our CUS scoring system. The “four-column
sign” and visibility of the PLIC were included as separate items
because in some infants the PLIC was visible, but there was no
clear “four-column sign”.
The CUS conducted on day 1 after birth was not predictive of
outcome in this study, which is in agreement with previous
studies.17,22 As mentioned above, it takes 24−72 h before brain
injury becomes visible as hyperechogenicity on CUS, unless the
onset of the injurious process is of antenatal onset.21 Conse-
quently, CUS within 6 h after birth had in a previous study a low
sensitivity of 42.1% and specificity of 60%.23 Nevertheless, CUS on
day 1 is recommended to identify antenatally acquired pathol-
ogy.5,10,11,32 We indeed found antenatally acquired pathology in
14 of the 83 infants in cohort I. Most of the antenatally acquired
lesions, i.e. germinal layer cysts, did not influence outcome and
can also be found in controls.17 However, in one infant a
porencephalic cyst was found that led to a mildly asymmetrical
motor outcome.
It was of interest to see that the RI was not associated with
adverse outcome in multivariable logistic regression analyses. The
RI was highly predictive in previous studies with non-cooled
infants, but appears to be less predictive in cooled infants, as
reported previously.20,21,31,33 Especially the positive predictive
value has decreased, so the observed outcome is better than the
expected outcome based on an abnormal RI. It has been
hypothesised that hypothermia has a direct effect on the cerebral
vessels or that hypothermia leads to a better neurodevelopmental
outcome but does not lead to a normalisation of the RI.33
The correlations between MRI and CUS in a study of Leijser et al.
were stronger than in our cohort (0.83 versus 0.67).26 This might
be explained by the fact that they used exactly the same scoring
systems for MRI and CUS and in our cohort the scoring systems
differed i.e. the cerebellum was included in the MRI scoring system
but not in the CUS scoring system. In cohort I there was a
moderate correlation between MRI and CUS, but predictive values
for MRI in the study of Weeke et al. were higher than for CUS in
our study.13 The most severely affected infants were too ill to
undergo an MRI. We speculate that these would have shown
severe MRI abnormalities, thereby improving the overall associa-
tion between CUS and MRI. The performance of the model was
good in both cohorts for both the cut-off value of ≥3 which can
potentially be used if the number of false negatives should be as
low as possible (i.e. for decisions about additional future
neuroprotective strategies) and for higher cut-off values that can
be preferable if the number of false positives should be as low as
possible (i.e. for considering redirection of care in combination
with neurophysiology and clinical features if MRI is not possible).
The interrater variability was moderate between all observers
implying that the interrater agreement among different hospitals
and observers would also be moderate. In a prospective cohort, in
which observers can be trained and the quality of CUS can be
guaranteed, interrater variability can be further improved.
Our study has several limitations. The first limitation is the
retrospective design; no images were routinely taken based on a
standard scan protocol. This resulted in poor quality of the images
due to non-optimal settings in some cases, the absence of certain
anatomical structures on the available images, the absence of CUS
on certain days and the absence of follow-up data. As a
consequence, a relatively large number of infants had to be
excluded. Secondly, neonatal death due to redirection of care was
Table 4. Performance of the model in cohort I and cohort II.
Cut-off valuea ≥3 ≥4 ≥5 ≥6 ≥7
Cohort I
Sensitivity 93% (76–99) 79% (60–91) 45% (27–64) 28% (13–47) 17% (7–36)
Specificity 86% (74–94) 88% (76–95) 92% (81–96) 98% (88–99) 100% (91–100)
PPV 79% (62–91) 79% (60–91) 76% (50–92) 89% (59–99) 100% (46–100)
NPV 96% (84–99) 88% (76–95) 75% (62–85) 71% (59–81) 68% (57–78)
Cohort II
Sensitivity 75% (47–92) 69% (41–88) 63% (36–84) 56% (31–79) 44% (21–69)
Specificity 94% (68–100) 94% (68–100) 100% (76–100) 100% (76–100) 100% (76–100)
PPV 92% (62–100) 92% (60–100) 100% (66–100) 100% (63–100) 100% (56–100)
NPV 79% (54–93) 75% (51–90) 73% (50–88) 70% (47–86) 64% (43–81)
PPV positive predictive value, NPV negative predictive value.
aA cut-off value of ≥3 means that an ultrasound score of 3 or more is defined as abnormal.
Table 5. Agreement between the observers in cohort I.
Observer 1 vs. 2 Observer 1 vs. 3 Observer 2 vs. 3
Spearman’s rho 0.74 (p= 0.001) 0.64 (p < 0.001) 0.72 (p= 0.001)
40
30
20
M
R
I s
co
re
 (to
tal
)
10
0
0 2 4 6
cUS score (total)
8 10 12
Fig. 3 The correlation between the MRI and CUS scoring system in
cohort I.
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defined as an adverse outcome; the decision was based on a
combination of clinical findings, neurophysiology and neuroima-
ging findings. Even so, we cannot exclude that this leads to some
bias because it is not certain that these infants would have
experienced problems later in life. However, in cohort I 17 of the
26 infants that died had a postmortem examination and in all
infants CUS findings were confirmed. Histopathology showed
more extensive damage than CUS, which has also been described
for MRI.34 Thirdly, because of the relatively small sample size and
the low incidence of adverse motor or cognitive outcome, our
study was not powered enough to perform sub-analyses for the
different outcome parameters. Finally, the distinction between the
categories “normal to mild” and “moderate” hyperechogenicity
remains subjective. Severe hyperechogenicity is easier to distin-
guish from the other categories. However, this is a reflection of
clinical practice and with this scoring system we finally have a
method that supports the clinician in their daily routine.
Furthermore, this scoring system provides a tool for prospective
clinical trials. Probably, the predictive value of the CUS scoring
system will further improve when researchers and clinicians will
focus even more on the quality using standard scan protocols in
prospective studies.
In summary, this novel CUS scoring system provides a tool to
structurally assess brain injury and predict outcome in HIE if MRI is
not feasible or available. It is an easy tool to use in clinical practice
and is the first validated CUS scoring system in HIE. In the future,
this CUS scoring system should be tested prospectively in infants
with HIE.
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